Aptose Biosciences Stock Performance
| APTO Stock | USD 0.24 0.03 11.11% |
The firm shows a Beta (market volatility) of -0.13, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Aptose Biosciences are expected to decrease at a much lower rate. During the bear market, Aptose Biosciences is likely to outperform the market. At this point, Aptose Biosciences has a negative expected return of -0.63%. Please make sure to confirm Aptose Biosciences' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Aptose Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Aptose Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:12 | Last Split Date 2014-10-06 |
1 | Acquisition by Whitehead Warren of 7000 shares of Aptose Biosciences at 2.6 subject to Rule 16b-3 | 08/30/2024 |
2 | Aptose Announces Results from Special Meeting of Shareholders | 09/05/2024 |
3 | Acquisition by Ashe Carol Gail of 100000 shares of Aptose Biosciences subject to Rule 16b-3 | 09/12/2024 |
4 | Disposition of 15400 shares by Whitehead Warren of Aptose Biosciences at 3.35 subject to Rule 16b-3 | 09/23/2024 |
5 | Aptose Biosciences Inc. Short Interest Up 520.2 percent in September | 09/27/2024 |
6 | Disposition of 60000 shares by Wilson Donald R. Jr. of Aptose Biosciences at 2.62 subject to Rule 16b-3 | 10/16/2024 |
7 | Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period DelveInsight | 10/21/2024 |
8 | Acquisition by Platzer Erich of 3333 shares of Aptose Biosciences at 2.0 subject to Rule 16b-3 | 11/01/2024 |
9 | Acquisition by Ashe Carol Gail of 3333 shares of Aptose Biosciences at 2.0 subject to Rule 16b-3 | 11/05/2024 |
10 | Aptose Biosciences GAAP EPS of -0.37 beats by 0.27 | 11/08/2024 |
11 | Aptose Biosciences Stock Price Passes Above Fifty Day Moving Average Heres Why | 11/13/2024 |
12 | Antisense and RNAi Therapeutics Market Research Report 2023-2030 Expanding Use in Chronic and Inflammatory Diseases Drives Long-Term Market Opportunities - Rese... | 11/21/2024 |
| Begin Period Cash Flow | 37 M |
Aptose |
Aptose Biosciences Relative Risk vs. Return Landscape
If you would invest 39.00 in Aptose Biosciences on August 24, 2024 and sell it today you would lose (15.00) from holding Aptose Biosciences or give up 38.46% of portfolio value over 90 days. Aptose Biosciences is currently does not generate positive expected returns and assumes 4.8406% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Aptose, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aptose Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aptose Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aptose Biosciences, and traders can use it to determine the average amount a Aptose Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1302
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | APTO |
Estimated Market Risk
| 4.84 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.63 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Aptose Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aptose Biosciences by adding Aptose Biosciences to a well-diversified portfolio.
Aptose Biosciences Fundamentals Growth
Aptose Stock prices reflect investors' perceptions of the future prospects and financial health of Aptose Biosciences, and Aptose Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aptose Stock performance.
| Return On Equity | -6.94 | ||||
| Return On Asset | -1.36 | ||||
| Current Valuation | (2.76 M) | ||||
| Shares Outstanding | 19.52 M | ||||
| Price To Earning | (1.80) X | ||||
| Price To Book | 67.84 X | ||||
| EBITDA | (52.27 M) | ||||
| Net Income | (51.21 M) | ||||
| Cash And Equivalents | 62.41 M | ||||
| Cash Per Share | 0.68 X | ||||
| Total Debt | 1.01 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.89 X | ||||
| Book Value Per Share | (0.36) X | ||||
| Cash Flow From Operations | (44.59 M) | ||||
| Earnings Per Share | (2.92) X | ||||
| Market Capitalization | 4.76 M | ||||
| Total Asset | 12.99 M | ||||
| Retained Earnings | (515.54 M) | ||||
| Working Capital | (3.38 M) | ||||
| Current Asset | 14.98 M | ||||
| Current Liabilities | 1.7 M | ||||
About Aptose Biosciences Performance
By examining Aptose Biosciences' fundamental ratios, stakeholders can obtain critical insights into Aptose Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Aptose Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.94) | (3.75) | |
| Return On Capital Employed | 22.96 | 24.11 | |
| Return On Assets | (3.94) | (3.75) | |
| Return On Equity | 17.65 | 18.53 |
Things to note about Aptose Biosciences performance evaluation
Checking the ongoing alerts about Aptose Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aptose Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aptose Biosciences generated a negative expected return over the last 90 days | |
| Aptose Biosciences has some characteristics of a very speculative penny stock | |
| Aptose Biosciences has high historical volatility and very poor performance | |
| Aptose Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (51.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aptose Biosciences currently holds about 62.41 M in cash with (44.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: Antisense and RNAi Therapeutics Market Research Report 2023-2030 Expanding Use in Chronic and Inflammatory Diseases Drives Long-Term Market Opportunities - ResearchAndMarkets.com |
- Analyzing Aptose Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aptose Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Aptose Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aptose Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aptose Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aptose Biosciences' stock. These opinions can provide insight into Aptose Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.92) | Return On Assets (1.36) | Return On Equity (6.94) |
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.